FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPF	PPROVAL							
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Cavanaugh Sarah						2. Issuer Name and Ticker or Trading Symbol Celldex Therapeutics, Inc. [CLDX]									eck all appli Directo	cable)		erson(s) to Issuer 10% Owner Other (specify	
(Last) (First) (Middle) C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD, SUITE 220						3. Date of Earliest Transaction (Month/Day/Year) 12/08/2021									below)		Affair	below) s & Admi	
(Street) HAMPTON NJ 08827					_ 4. If	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person											on		
(City)	(S	tate)	(Zip)																
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					ection	tion 2A. Deemed Execution Date,		3. Transa	Transaction Disposed Of (Disposed Of Code (Instr.			f, or Beneficiall s Acquired (A) or of (D) (Instr. 3, 4 and 5			5. Amount of Securities Beneficially Owned Following		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
							Code	v	Amount	t (A) or (D)		ce	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)		
Common Stock 12/				12/08	/2021	2021		М		1,857	' A \$9		.016	5 2,	2,265		D		
Common Stock 12/08					/2021	2021		М		5,466	5,466 A		10.38	7,731			D		
Common	Stock			12/08	/2021				S ⁽¹⁾		7,323 ⁽¹⁾ D			\$40	408			D	
		Т	able II -								osed of converti				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/D	ned n Date,	4. Transa Code (i 8)	ection	5. Number on of		6. Date Exercis Expiration Dat (Month/Day/Ye		sable and e	7. Title a Amount Securiti Underly Derivati (Instr. 3	nd of es ng /e Secu	8. D S (l	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s ally	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amo or Num of Sha	ber					
Incentive Stock Option (Right to Buy)	\$9.0165	12/08/2021			М			1,857	(2)		06/13/2028	Commo Stock	1,8	57	\$0.00	11,458	3	D	
Incentive Stock Option (Right to Buy)	\$10.38	12/08/2021			М			5,466	(3)		06/18/2030	Commo: Stock	5,4	66	\$0.00	78,534	1	D	

Explanation of Responses:

- 1. The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 10, 2021.
- 2.25% vested on June 13,2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
- 3. 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

/s/ Sam Martin, attorney-in-fact 12/10/2021 for Sarah Cavanaugh

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.